Enhancement of cell-specific transgene expression from a Tet-Off regulatory system using a transcriptional amplification strategy in the rat brain

Journal of Gene Medicine

Volumn 10, Issue 5, 2008, Pages 583-592

  Liu, Beihui ^a   Wang, Shu ^b,c   Brenner, Michael ^d   Paton, Julian F R ^a   Kasparov, Sergey ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^d University of Alabama at Birmingham   (United States)

Author keywords

Astrocytes; Cell targeting; CNS; Doxycycline; Gene transfer; Lentriviral vectors; Neurons; Tetracycline regulated gene expression; Transcriptional amplification

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; LENTIVIRUS VECTOR; RED FLUORESCENT PROTEIN; SYNAPSIN I; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR GAL4; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL CULTURE; CELL SPECIFICITY; CONTROLLED STUDY; DNA BINDING; ENHANCER REGION; GENE EXPRESSION; GENE TARGETING; GENETIC CODE; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR CLONING; NERVE CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; RAT; TRANSCRIPTIONAL AMPLIFICATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BRAIN; GENE EXPRESSION REGULATION; LENTIVIRUS; PROMOTER REGIONS (GENETICS); RATS; RESPONSE ELEMENTS; TETRACYCLINE; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSDUCTION, GENETIC; TRANSGENES;

RATTUS;

EID: 44449094037     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1178     Document Type: Article

References (49)

1. + sensing. Neuron 2007; 54: 59-72.
2. Marty N, et al. Regulation of glucagon secretion by glucose transporter type 2 (glut2) and astrocyte-dependent glucose sensors. J Clin Invest 2005; 115: 3545-3553.
3. Lonergan T, Teschemacher AG, Hwang DY, Kim KS, Pickering AE, Kasparov S. Targeting brain stem centers of cardiovascular control using adenoviral vectors: impact of promoters on transgene expression. Physiol Genomics 2005; 20: 165-172.
4. Kasparov S, Teschemacher AG, Hwang DY, Kim KS, Lonergan T, Paton JF. Viral vectors as tools for studies of central cardiovascular control. Prog Biophys Mol Biol 2004; 84: 251-277.
5. Hwang DY, Carlezon WA Jr, Isacson O, Kim KS. A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons. Hum Gene Ther 2001; 12: 1731-1740.
6. Nettelbeck DM, Jerome V, Muller R. Gene therapy: designer promoters for turnout targeting. Trends Genet 2000; 16: 174-181.
7. Liu BH, Wang X, Ma YX, Wang S. CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression. Gene Ther 2004; 11: 52-60.
8. Nettelbeck DM, Jerome V, Muller R. A strategy for enhancing the transcriptional activity of weak cell type-specific promoters. Gene Ther 1998; 5: 1656-1664.
9. Miller N, Whelan J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum Gene Ther 1997; 8: 803-815.
10. Glover CP, Bienemann AS, Heywood DJ, Cosgrave AS, Uney JB. Adenoviral-mediated, high-level, cell-specific transgene expression: a SYN1-WPRE cassette mediates increased transgene expression with no loss of neuron specificity. Mol Ther 2002; 5: 509-516.
11. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551.
12. Goverdhana S, et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther 2005; 12: 189-211.
13. Zhu Z, Zheng T, Lee CG, Homer RJ, Elias JA. Tetracycline-controlled transcriptional regulation systems: advances and application in transgenic animal modeling. Semin Cell Dev Biol 2002; 13: 121-128.
14. Agha-Mohammadi S, O'Malley M, Etemad A, Wang Z, Xiao X, Lotze MT. Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med 2004; 6: 817-828.
15. Pluta K, Luce MJ, Bao L, gha-Mohammadi S, Reiser J. Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters. J Gene Med 2005; 7: 803-817.
16. http://www.clontech.com/images/pt/PT3722-5.pdf
17. Teschemacher AG, Paton JFR, Kasparov S. Imaging living central neurones using viral gene transfer. Adv Drug Deliver Rev 2005; 57: 79-93.
18. Ralph GS, Bienemann A, Harding TC, Hopton M, Henley J, Uney JB. Targeting of tetracycline-regulatable transgene expression specifically to neuronal and glial cell populations using adenoviral vectors. Neuroreport 2000; 11: 2051-2055.
19. Lee YB, et al. Increased utility in the CNS of a powerful neuron-specific tetracycline-regulatable adenoviral system developed using a post-transcriptional enhancer. J Gene Med 2005; 7: 576-583.
20. Harding TC, Geddes BJ, Murphy D, Knight D, Uney JB. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nat Biotechnol 1998; 16: 553-555.
21. Smith-Arica JR, Morelli AE, Larregina AT, Smith J, Lowenstein PR, Castro MG. Cell-type-specific and regulatable transgenesis in the adult brain: adenovirus-encoded combined transcriptional targeting and inducible transgene expression. Mol Ther 2000; 2: 579-587.
22. Liu BH, et al. GAL4-NF-kappaB fusion protein augments transgene expression from neuronal promoters in the rat brain. Mol Ther 2006; 14: 872-882.
23. Iyer M, Wu L, Carey M, Wang Y, Smallwood A, Gambhir SS. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci USA 2001; 98: 14595-14600.
24. Kugler S, et al. Neuron-specific expression of therapeutic proteins: evaluation of different cellular promoters in recombinant adenoviral vectors. Mol Cell Neurosci 2001; 17: 78-96.
25. Su M, Hu H, Lee Y, d'Azzo A, Messing A, Brenner M. Expression specificity of GFAP transgenes. Neurochem Res 2004; 29: 2075-2093.
26. Duale H, Kasparov S, Paton JF, Teschernacher AG. Differences in transductional tropism of adenoviral and lentiviral vectors in the rat brainstem. Exp Physiol 2005; 90: 71-78.
27. Coleman JE, et al. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics 2003; 12: 221-228.
28. Kaltschmidt C, Kaltschmidt B, Neumann H, Wekerle H, Baeuerle PA. Constitutive NF-kappa B activity in neurons. Mol Cell Biol 1994; 14: 3981-3992.
29. Bhakar AL, et al. Constitutive nuclear factor-kappa B activity is required for central neuron survival. J Neurosci 2002; 22: 8466-8475.
30. Meffert MK, Baltimore D. Physiological functions for brain NF-kappaB. Trends Neurosci 2005; 28: 37-43.
31. Mattson MP. NF-kappaB in the survival and plasticity of neurons. Neurochem Res 2005; 30: 883-893.
32. Memet S. NF-kappaB functions in the nervous system: from development to disease. Biochem Pharmacol 2006; 72: 1180-1195.
33. Nolan GP, Ghosh S, Liou HC, Tempst P, Baltimore D. DNA-binding and I-kappa-B inhibition of the cloned P65 subunit of Nf-kappa-B, A Rel-related polypeptide. Cell 1991; 64: 961-969.
34. Silver PA, Keegan LP, Ptashne M. Amino terminus of the yeast Ga14 gene-product is sufficient for nuclear-localization. Proc Natl Acad Sci USA 1984; 81: 5951-5955.
35. Verkhusha VV, et al. High stability of Discosoma DsRed as compared to Aequorea EGFP. Biochemistry 2003; 42: 7879-7884.
36. Ghersa P, Gobert RP, Sattonnet-Roche P, Richards CA, Merlo PE, van Hooft HR. Highly controlled gene expression using combinations of a tissue-specific promoter, recombinant adenovirus and a tetracycline-regulatable transcription factor. Gene Ther 1998; 5: 1213-1220.
37. Grahame-Smith DG, Aronson JK. Oxford Textbook of Clinical Pharmacology and Drug Therapy, Oxford University Press: London, 1992.
38. Corti O, Sanchez-Capelo A, Colin P, Hanoun N, Hamon M, Mallet J. Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. Proc Natl Acad Sci U S A 1999; 96: 12120-12125.
39. Corti O, et al. A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors. Nat Biotechnol 1999; 17: 349-354.
40. Harding TC, Geddes BJ, Noel JD, Murphy D, Uney JB. Tetracycline-regulated transgene expression in hippocampal neurones following transfection with adenoviral vectors. J Neurochem 1997; 69: 2620-2623.
41. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A 2005; 102: 13212-13217.
42. Walker PS, Hengge UR, Udey MC, Aksentijevich I, Vogel JC. Viral interference during simultaneous transduction with two independent helper-free retroviral vectors. Hum Gene Ther 1996; 7: 1131-1138.
43. Federico M, et al. Anti-HIV viral interference induced by retroviral vectors expressing a nonproducer HIV-1 variant. Acta Haematol 1996; 95: 199-203.
44. D'Aloja P, et al. gag, vif, and nef genes contribute to the homologous viral interference induced by a nonproducer human immunodeficiency virus type 1 (HIV-1) variant: identification of novel HIV-1-inhibiting viral protein mutants. J Virol 1998; 72: 4308-4319.
45. Potash MJ, Volsky DJ. Viral interference in HIV-1 infected cells. Rev Med Virol 1998; 8: 203-211.
46. Bernier R, Tremblay M. Homologous interference resulting from the presence of defective particles of human immunodeficiency virus type 1. J Virol 1995; 69: 291-300.
47. Volsky DJ, Simm M, Shababuddin M, Li GR, Chao W, Potash MJ. Interference to human immunodeficiency virus type 1 infection in the absence of downmodulation of the principal virus receptor, CD4. J Virol 1996; 70: 3823-3833.
48. Frimpong K, Spector SA. Cotransduction. of nondividing cells using lentiviral vectors. Gene Ther 2000; 7: 1562-1569.
49. Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stornatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 1997; 71: 5871-5877.